WallStreetZenWallStreetZen

NASDAQ: RANI
Rani Therapeutics Holdings Inc Stock Forecast, Predictions & Price Target

Analyst price target for RANI

Based on 3 analysts offering 12 month price targets for Rani Therapeutics Holdings Inc.
Min Forecast
$8.00+21.95%
Avg Forecast
$9.67+47.36%
Max Forecast
$12.00+82.93%

Should I buy or sell RANI stock?

Based on 3 analysts offering ratings for Rani Therapeutics Holdings Inc.
Strong Buy
Strong Buy
1 analysts 33.33%
Buy
2 analysts 66.67%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their RANI stock forecasts and price targets.

RANI stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-03-27
lockedlocked$00.00+00.00%2024-03-25
lockedlocked$00.00+00.00%2024-02-06

1 of 1

Forecast return on equity

Is RANI forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.16%

Forecast return on assets

Is RANI forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

RANI revenue forecast

What is RANI's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$30.2M
Avg 2 year Forecast
$80.1M
Avg 3 year Forecast
$101.1M

RANI vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
RANI$6.56$9.67+47.36%Strong Buy
TNYA$4.22$15.75+273.22%Strong Buy
LXEO$12.16$21.20+74.34%Strong Buy
SLDB$8.54$20.33+138.09%Strong Buy
GUTS$6.72$18.00+167.86%Strong Buy

Rani Therapeutics Holdings Stock Forecast FAQ

Is Rani Therapeutics Holdings Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: RANI) stock is to Strong Buy RANI stock.

Out of 3 analysts, 1 (33.33%) are recommending RANI as a Strong Buy, 2 (66.67%) are recommending RANI as a Buy, 0 (0%) are recommending RANI as a Hold, 0 (0%) are recommending RANI as a Sell, and 0 (0%) are recommending RANI as a Strong Sell.

If you're new to stock investing, here's how to buy Rani Therapeutics Holdings stock.

What is RANI's revenue growth forecast for 2026-2028?

(NASDAQ: RANI) Rani Therapeutics Holdings's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.04%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.92%.

Rani Therapeutics Holdings's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast RANI's revenue for 2026 to be $1,514,750,218, with the lowest RANI revenue forecast at $1,514,750,218, and the highest RANI revenue forecast at $1,514,750,218. On average, 1 Wall Street analysts forecast RANI's revenue for 2027 to be $4,016,094,370, with the lowest RANI revenue forecast at $4,016,094,370, and the highest RANI revenue forecast at $4,016,094,370.

In 2028, RANI is forecast to generate $5,070,902,221 in revenue, with the lowest revenue forecast at $2,259,084,432 and the highest revenue forecast at $7,882,720,011.

What is RANI's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: RANI) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is RANI's Price Target?

According to 3 Wall Street analysts that have issued a 1 year RANI price target, the average RANI price target is $9.67, with the highest RANI stock price forecast at $12.00 and the lowest RANI stock price forecast at $8.00.

On average, Wall Street analysts predict that Rani Therapeutics Holdings's share price could reach $9.67 by Mar 27, 2025. The average Rani Therapeutics Holdings stock price prediction forecasts a potential upside of 47.36% from the current RANI share price of $6.56.

What is RANI's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: RANI) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.